RSPO3 and colorectal carcinoma: Interestingly, combining an anti-RSPO3 antibody (OMP-131R10) with paclitaxel also reduced tumor growth and nuclear β-catenin expression in 8 APC mutant CRC PDX models when compared to monotherapy [23].